A Phase 2b Study of Zagociguat in Patients With MELAS

Key facts

Sponsor

Tisento Therapeutics

Intervention

zagociguat 15mg(drug)

Enrollment

43 enrolled

Eligibility

18-75 years · All sexes

Timeline

2024 – 2026

Study locations (20)

• UC San Diego - Altman Clinical and Translational Research Institute, La Jolla, California, United States
• Children's Hospital of Colorado, Aurora, Colorado, United States
• Rare Disease Research, Atlanta, Georgia, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Columbia University Irving Medical Center, New York, New York, United States
• Mount Sinai - Ichan School of Medicine, New York, New York, United States
• Akron Children's Hospital, Akron, Ohio, United States
• Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
• Baylor College of Medicine, Houston, Texas, United States
• University of Texas Medical School at Houston, Houston, Texas, United States
• Neuroscience Research Australia, Sydney, New South Wales, Australia
• Royal Melbourne Hospital, Melbourne, Victoria, Australia
• Shared Health/University of Manitoba, Winnipeg, Manitoba, Canada
• McMaster University Medical Center, Hamilton, Ontario, Canada
• University Hospital Bonn, Bonn, Germany
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for MELAS

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT06961344
  An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
  Tisento Therapeutics
• RECRUITINGPHASE2NCT06644534
  A Study to Assess TTI-0102 vs Placebo in MELAS Patients
  Thiogenesis Therapeutics, Inc.

See all trials for MELAS →